Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer
Weekly Trastuzumab (Herceptin) and Irinotecan in Patients With HER-2 Positive Advanced Breast Cancer: A Phase II Trial
Status: Enrolling
Updated:  1/12/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer
Weekly Trastuzumab (Herceptin) and Irinotecan in Patients With HER-2 Positive Advanced Breast Cancer: A Phase II Trial
Status: Enrolling
Updated: 1/12/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  1/13/2018
University of Kansas Hospital - Westwood Cancer Center
mi
from
Westwood, KA
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 1/13/2018
University of Kansas Hospital - Westwood Cancer Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  1/13/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 1/13/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  1/13/2018
Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 1/13/2018
Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer
Phase II Study of Acolbifene in Pre-Menopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  1/15/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer
Phase II Study of Acolbifene in Pre-Menopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 1/15/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer
A Phase II Study of Accelerated Hypofractionated Radiotherapy (AHF-RT) After Breast Conserving Surgery (BCS) in Medically Underserved Patients
Status: Enrolling
Updated:  1/15/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer
A Phase II Study of Accelerated Hypofractionated Radiotherapy (AHF-RT) After Breast Conserving Surgery (BCS) in Medically Underserved Patients
Status: Enrolling
Updated: 1/15/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Northwestern University Medical Center
mi
from
Chicago, IL
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Northwestern University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Ohio State Unviersity Medical Center
mi
from
Columbus, OH
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Ohio State Unviersity Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Univ of Washington
mi
from
Seattle, WA
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
A Dose-escalation Study in Subjects With Advanced Malignancies
A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Philadelphia, PA
A Dose-escalation Study in Subjects With Advanced Malignancies
A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Dose-escalation Study in Subjects With Advanced Malignancies
A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Chicago, IL
A Dose-escalation Study in Subjects With Advanced Malignancies
A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Birmingham, AL
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Louisville, KY
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Ann Arbor, MI
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Albuquerque, NM
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Tulsa, OK
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Portland, OR
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Hot Springs, AR
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Burbank, CA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Burbank, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Santa Monica, CA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Denver, CO
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Stamford, CT
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Stamford, CT
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Boynton Beach, FL
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
mi
from
Elks Grove Village, IL
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
mi
from
Elks Grove Village, IL
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Sioux City, IA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Sioux City, IA
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Lexington, KY
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Worcester, MA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Worcester, MA
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Detroit, MI
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Grand Rapids, MI
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Novi, MI
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Novi, MI
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Minneapolis, MN
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Voorhees, NJ
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Lake Success, NY
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Durham, NC
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Hickory, NC
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Canton, OH
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Dayton, OH
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Bend, OR
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Bend, OR
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Pittsburgh, PA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Knoxville, TN
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
San Antonio, TX
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Richmond, VA
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Green Bay, WI
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Green Bay, WI
Click here to add this to my saved trials
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Fort Myers, FL
Study of Ruxolitinib in Pancreatic Cancer Patients
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials